Merck & Company Inc (MRK)vsOrganogenesis Holdings Inc (ORGO)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
ORGO
Organogenesis Holdings Inc
$2.35
+2.17%
HEALTHCARE · Cap: $307.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 11423% more annual revenue ($65.01B vs $564.17M). MRK leads profitability with a 28.1% profit margin vs 6.6%. MRK trades at a lower P/E of 15.2x. ORGO earns a higher WallStSmart Score of 67/100 (B-).
MRK
Buy59
out of 100
Grade: C
ORGO
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+80.1%
Fair Value
$18.81
Current Price
$2.35
$16.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Earnings expanding 555.0% YoY
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 78.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while ORGO is a hypergrowth play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.48 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
ORGO scores higher overall (67/100 vs 59/100) and 78.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?